The results from this study thus reveal a yet undefined MTA1/MDM2/DNA-PK/H1.2 axis in HCC that can be potentially targeted by proteasomal inhibitors to reverse MTA1's role in HCC. The gene discussed is PRKDC; the disease is hepatocellular carcinoma.